Desvenlafaxine versus escitalopram in major depression with anxiety : a randomized clinical trial

Phase 4

Completed

Conditions: Health Condition 1: null- Major depressive disorders with anxiety symptoms

Registration Number: CTRI/2012/08/002895

Lead Sponsor: Department of Pharmacology IPGMER Kolkata

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 85

Inclusion Criteria

subjects of major depressive disorder with symptoms of anxiety with HAM score of seven to eighteen

baseline HAMA score more than or equal to twelve

Subjects must be willing to give written informed consent

Exclusion Criteria

subjects with age less tha eighteen or more than sixty

Pregnant and lactating women

Baseline HAMD score less than seven or more than eighteen

Baseline HAMA score less than 12

Subjects with psychotic features

Subjects with suicidality catatonic features

Subjects on any antidepressant medications in the last two months

Subjects with concurrent severe medical disorders like uncontrolled diabetes hypertension ischemic heart disease chronic renal failure cirrhosis any malignancy etc

Subjects with history of substance abuse in the last two years

Subjects with mixed depression and anxiety disorder or any other episodes of other mood disorder bipolar disorder dysthymia etc

Subjects with any other psychiatric disorders

Subjects on other concurrent medications known to have drug interact with the study medications like other SSRI SNRI tricyclic antidepressants etc

Subjects with past history of anaphylaxis or hypersensitivity to any of the study medications

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
changes from baseline to study end of seventeen item HAMD depression rating scale <br/ ><br>changes from baselien to study end of HAM anxiety rating scaleTimepoint: Changes in HAMD 17 item score at baseline (day 0) and at study end (week 8)

Secondary Outcome Measures

Name	Time	Method
Precentage of subjects achieving at least 50% reduction of baseline scores in HAMD 17 item <br/ ><br>percentage of subjects who have at least one Adverse Drug eventTimepoint: Baseline to study end -8 weeks